Mov Disord Vol 34, Suppl 2 Archives - Page 204 of 217 - MDS Abstracts

2019 International Congress
Park-Ease Trial: A Randomized Controlled Trial to Study the Efficacy of Exercises in Early-Stage Parkinson’s Disease
R. Swarnakar, S. Wadhwa, S. V, V. Goyal, V. Sreenivas (New Delhi, India)
Objective: To evaluate the efficacy of exercises in early-stage Parkinson’s Disease by observing improvement in motor symptoms assessed by Unified Parkinson’s Disease Rating Scale (UPDRS)…
2019 International Congress
Misdiagnosis in blepharospasm: the common imitators which should not be missed
S. Desai, S. Thati, D. Desai (Anand, India)
Objective: Blepharospasm is a focal dystonia whose diagnosis is completely clinical with no blood or imaging biomarker. We observed that sometimes, patients with other disorders…
2019 International Congress
Stiff-Person Syndrome and Limbic Encephalopathy Associated With GAD-antibody: A Case Report
SL. Li, YM. Yang, HZ. Guan, XH. Wan, HT. Ren (Peking, China)
Objective: To extend spectrum of glutamic acid decarboxylase(GAD) associated disorders by reporting a case Background: GADA associated disorders include a broad and clinically heterogeneous group…
2019 International Congress
Satisfaction with care in late stage Parkinson’s disease
K. Rosqvist, P. Hagell, S. Iwarsson, M. Nilsson, P. Odin (Lund, Sweden)
Objective: To assess satisfaction with care in patients with late stage Parkinson’s disease (PD) and to identify factors associated with patient satisfaction with care. Moreover,…
2019 International Congress
Characterization of impulsivity in Colombian patients with Huntington’s disease
L. Colmenares, C. Rodriguez, W. Fernandez (Bogotá, Colombia)
Objective: To describe impulsivity in patients with Huntington's disease using a self-report scale and through an objective test of the inhibition capacity. Describe the demographic…
2019 International Congress
Comorbidities and medications in Huntington’s disease, Parkinson’s disease and the general population in a US claims database
L. Ishihara, E. Wild, D. Oliveri (Welwyn Garden City, United Kingdom)
Objective: This study characterises the comorbidities and symptoms, and treatment patterns of patients with Huntington’s disease (HD) vs patients with Parkinson’s disease (PD) vs the…
2019 International Congress
Patient and physician perspectives on the care and assistance needs in Huntington’s disease
K. Raimundo, R. Tan, T. To, J. de Courcy, U. Ondhia, H. Rickards, M. Nance (South San Francisco, CA, USA)
Objective: To describe the assistance needs of people with Huntington’s disease (HD) across different countries. Background: HD is a genetic, neurodegenerative and ultimately fatal disease…
2019 International Congress
Ancillary Service Utilization and Impact in Huntington’s Disease
J. Yomtoob, C. Yeh, D. Bega (Chicago, IL, USA)
Objective: To determine which Huntington’s disease (HD) patient characteristics correlate with ancillary service utilization. To examine the longitudinal impact of ancillary therapies on clinical characteristics.…
2019 International Congress
High dose off-label Safinamide treatment in Young Onset Parkinson’s Disease patients
C. Carrarini, M. Russo, F. Barbone, F. Dono, M. Rispoli, M. Onofrj, A. Thomas (Chieti, Italy)
Objective: To assess tolerability and efficacy of high dose Safinamide treatment in Young Onset Parkinson’s Disease (YOPD) patients with dystonia and history of impulse controls…
2019 International Congress
Utilization of Monotherapy and Combination Therapies in Advanced Parkinson Disease Patients During Levodopa-Carbidopa Intestinal Gel Treatment from the COSMOS Study
A. Fasano, JC. Parra, T. Gurevich, R. Jech, N. Kovács, P. Svenningsson, J. Szász, L. Bergmann, A. Johnson, O. Sanchez-Soliño, Z. Tang, L. Vela-Desojo (Toronto, ON, Canada)
Objective: Assess the percentages of advanced Parkinson’s disease (APD) patients treated with levodopa-carbidopa intestinal gel (LCIG) as a monotherapy or with add-on PD medications and…